Stock RGEN REPLIGEN CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Repligen Corporation

Equities

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
166.6 USD +0.56% Intraday chart for Repligen Corporation +6.01% -7.35%
Apr. 08 RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating MT
Mar. 20 Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,815 10,414 14,643 9,401 10,039 9,302 - -
Enterprise Value (EV) 1 4,520 9,972 14,405 9,062 9,357 9,025 8,915 8,894
P/E ratio 210 x 173 x 118 x 52.3 x 243 x 314 x 112 x 81.7 x
Yield - - - - - - - -
Capitalization / Revenue 17.8 x 28.4 x 21.8 x 11.7 x 15.7 x 14.6 x 12.6 x 10.8 x
EV / Revenue 16.7 x 27.2 x 21.5 x 11.3 x 14.6 x 14.2 x 12.1 x 10.3 x
EV / EBITDA 63.5 x 92.5 x 62.5 x 36.7 x 73.1 x 76.6 x 51.9 x 41 x
EV / FCF 104 x 248 x 277 x 104 x 120 x 144 x 81.5 x 59.1 x
FCF Yield 0.96% 0.4% 0.36% 0.96% 0.83% 0.69% 1.23% 1.69%
Price to Book 4.29 x 6.86 x 8.67 x 4.92 x 5.09 x 4.67 x 4.43 x 4.11 x
Nbr of stocks (in thousands) 52,059 54,344 55,289 55,524 55,832 55,839 - -
Reference price 2 92.50 191.6 264.8 169.3 179.8 166.6 166.6 166.6
Announcement Date 2/20/20 2/24/21 2/17/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 270.2 366.3 670.5 801.5 638.8 637.8 739.1 862.4
EBITDA 1 71.13 107.9 230.5 246.9 128 117.8 171.9 217
EBIT 1 63.52 98.05 215.2 232.2 94.29 86.67 133.6 180.3
Operating Margin 23.5% 26.77% 32.09% 28.97% 14.76% 13.59% 18.08% 20.9%
Earnings before Tax (EBT) 1 26.15 59.22 153.5 219.1 64.13 38.24 115.5 154
Net income 1 21.41 59.93 128.3 186 41.58 43.55 88.78 136.5
Net margin 7.92% 16.36% 19.13% 23.2% 6.51% 6.83% 12.01% 15.83%
EPS 2 0.4400 1.110 2.240 3.240 0.7400 0.5300 1.486 2.040
Free Cash Flow 1 43.26 40.17 51.93 87.25 77.7 62.66 109.4 150.6
FCF margin 16.01% 10.97% 7.74% 10.89% 12.16% 9.82% 14.81% 17.46%
FCF Conversion (EBITDA) 60.83% 37.25% 22.52% 35.34% 60.72% 53.21% 63.66% 69.39%
FCF Conversion (Net income) 202.07% 67.03% 40.48% 46.92% 186.87% 143.89% 123.26% 110.3%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/20/20 2/24/21 2/17/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 178.2 186.5 206.4 207.6 200.7 186.8 182.7 159.2 141.2 155.7 150.1 153.7 161.5 170.4 173.4
EBITDA 1 60.52 61.6 72.21 67.69 57.95 49.06 48.86 38.45 14.46 26.19 24.3 27.46 30.97 35.04 36.38
EBIT 1 56.96 55.91 67.37 65.56 58.15 41.13 40.85 29.45 5.167 18.82 16.49 19.66 23.09 27.44 28.05
Operating Margin 31.96% 29.97% 32.64% 31.57% 28.97% 22.02% 22.37% 18.5% 3.66% 12.08% 10.99% 12.79% 14.3% 16.1% 16.18%
Earnings before Tax (EBT) 1 41.23 34.85 58.93 59.76 47.47 52.99 36.09 25.16 11.64 -8.757 5.644 6.187 11.05 15.36 20.33
Net income 1 33.5 29.11 46.96 49.86 40.4 48.73 28.83 20.06 18.17 -25.49 6.538 7.867 10.77 13.16 19.55
Net margin 18.8% 15.61% 22.75% 24.01% 20.13% 26.09% 15.78% 12.61% 12.87% -16.37% 4.36% 5.12% 6.67% 7.72% 11.27%
EPS 2 0.5800 0.5000 0.8100 0.8800 0.7100 0.8500 0.5100 0.3500 0.3200 -0.4600 0.0750 0.1000 0.1575 0.2000 0.2800
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/28/21 2/17/22 4/27/22 8/2/22 11/1/22 2/22/23 5/2/23 8/2/23 10/31/23 2/21/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 296 442 238 339 682 276 386 408
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 43.3 40.2 51.9 87.2 77.7 62.7 109 151
ROE (net income / shareholders' equity) 6.27% 6.88% 10.7% 10.3% 5.07% 3.32% 5.25% 5.89%
ROA (Net income/ Total Assets) 4.83% 5.39% 8.23% 7.72% 3.68% 2.63% 4.36% 5.07%
Assets 1 443.3 1,111 1,560 2,408 1,130 1,655 2,034 2,692
Book Value Per Share 2 21.50 27.90 30.60 34.40 35.30 35.70 37.60 40.50
Cash Flow per Share 2 1.260 - 3.860 4.100 2.170 1.640 2.520 3.060
Capex 1 18.5 22.5 67.1 84.8 36.2 40.1 44 43.2
Capex / Sales 6.85% 6.13% 10.01% 10.58% 5.67% 6.28% 5.95% 5.01%
Announcement Date 2/20/20 2/24/21 2/17/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Repligen Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
166.6 USD
Average target price
210.9 USD
Spread / Average Target
+26.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
REPLIGEN CORPORATION Stock Repligen Corporation
-7.35% 9.3B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. RGEN Stock
  4. Financials Repligen Corporation